Evan D Bander1,2, Melissa Yuan1, Anne S Reiner3, Katherine S Panageas3, Åse M Ballangrud4, Cameron W Brennan1, Kathryn Beal5, Viviane Tabar1, Nelson S Moss1. 1. Department of Neurosurgery and Brain Metastasis Center, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Neurosurgery, New York-Presbyterian Hospital/Weill Cornell Medical College, New York, New York. 3. Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: Adjuvant stereotactic radiosurgery (SRS) improves the local control of resected brain metastases (BrM). However, the dependency of long-term outcomes on SRS timing relative to surgery remains unclear. METHODS: Retrospective analysis of patients treated with metastasectomy-plus-adjuvant SRS at Memorial Sloan Kettering Cancer Center (MSK) between 2013 and 2016 was conducted. Kaplan-Meier methodology was used to describe overall survival (OS) and cumulative incidence rates were estimated by type of recurrence, accounting for death as a competing event. Recursive partitioning analysis (RPA) and competing risks regression modeling assessed prognostic variables and associated events of interest. RESULTS: Two hundred and eighty-two patients with BrM had a median OS of 1.5 years (95% CI: 1.2-2.1) from adjuvant SRS with median follow-up of 49.8 months for survivors. Local surgical recurrence, other simultaneously SRS-irradiated site recurrence, and distant central nervous system (CNS) progression rates were 14.3% (95% CI: 10.1-18.5), 4.9% (95% CI: 2.3-7.5), and 47.5% (95% CI: 41.4-53.6) at 5 years, respectively. Median time-to-adjuvant SRS (TT-SRS) was 34 days (IQR: 27-39). TT-SRS was significantly associated with surgical site recurrence rate (P = 0.0008). SRS delivered within 1 month resulted in surgical site recurrence rate of 6.1% (95% CI: 1.3-10.9) at 1-year, compared to 9.2% (95% CI: 4.9-13.6) if delivered between 1 and 2 months, or 27.3% (95% CI: 0.0-55.5) if delivered >2 months after surgery. OS was significantly lower for patients with TT-SRS >~2 months. Postoperative length of stay, discharge to a rehabilitation facility, urgent care visits, and/or disease recurrence between surgery and adjuvant SRS associated with increased TT-SRS. CONCLUSIONS: Adjuvant SRS provides durable local control. However, delays in initiation of postoperative SRS can decrease its efficacy.
BACKGROUND: Adjuvant stereotactic radiosurgery (SRS) improves the local control of resected brain metastases (BrM). However, the dependency of long-term outcomes on SRS timing relative to surgery remains unclear. METHODS: Retrospective analysis of patients treated with metastasectomy-plus-adjuvant SRS at Memorial Sloan Kettering Cancer Center (MSK) between 2013 and 2016 was conducted. Kaplan-Meier methodology was used to describe overall survival (OS) and cumulative incidence rates were estimated by type of recurrence, accounting for death as a competing event. Recursive partitioning analysis (RPA) and competing risks regression modeling assessed prognostic variables and associated events of interest. RESULTS: Two hundred and eighty-two patients with BrM had a median OS of 1.5 years (95% CI: 1.2-2.1) from adjuvant SRS with median follow-up of 49.8 months for survivors. Local surgical recurrence, other simultaneously SRS-irradiated site recurrence, and distant central nervous system (CNS) progression rates were 14.3% (95% CI: 10.1-18.5), 4.9% (95% CI: 2.3-7.5), and 47.5% (95% CI: 41.4-53.6) at 5 years, respectively. Median time-to-adjuvant SRS (TT-SRS) was 34 days (IQR: 27-39). TT-SRS was significantly associated with surgical site recurrence rate (P = 0.0008). SRS delivered within 1 month resulted in surgical site recurrence rate of 6.1% (95% CI: 1.3-10.9) at 1-year, compared to 9.2% (95% CI: 4.9-13.6) if delivered between 1 and 2 months, or 27.3% (95% CI: 0.0-55.5) if delivered >2 months after surgery. OS was significantly lower for patients with TT-SRS >~2 months. Postoperative length of stay, discharge to a rehabilitation facility, urgent care visits, and/or disease recurrence between surgery and adjuvant SRS associated with increased TT-SRS. CONCLUSIONS: Adjuvant SRS provides durable local control. However, delays in initiation of postoperative SRS can decrease its efficacy.
Authors: R A Patchell; P A Tibbs; J W Walsh; R J Dempsey; Y Maruyama; R J Kryscio; W R Markesbery; J S Macdonald; B Young Journal: N Engl J Med Date: 1990-02-22 Impact factor: 91.245
Authors: Robert H Press; Sarah L Shafer; Renjian Jiang; Zachary S Buchwald; Mustafa Abugideiri; Sibo Tian; Tiffany M Morgan; Madhusmita Behera; Soma Sengupta; Alfredo D Voloschin; Jeffrey J Olson; Shaakir Hasan; Deborah T Blumenthal; Walter J Curran; Bree R Eaton; Hui-Kuo G Shu; Jim Zhong Journal: Cancer Date: 2020-04-28 Impact factor: 6.860
Authors: Emory R McTyre; Adam G Johnson; Jimmy Ruiz; Scott Isom; John T Lucas; William H Hinson; Kounosuke Watabe; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Neuro Oncol Date: 2017-04-01 Impact factor: 12.300
Authors: Paul W Sperduto; Samuel T Chao; Penny K Sneed; Xianghua Luo; John Suh; David Roberge; Amit Bhatt; Ashley W Jensen; Paul D Brown; Helen Shih; John Kirkpatrick; Amanda Schwer; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan Knisely; Christina Maria Sperduto; Minesh Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2009-11-26 Impact factor: 7.038
Authors: Daniel N Cagney; Nayan Lamba; Sumi Sinha; Paul J Catalano; Wenya Linda Bi; Brian M Alexander; Ayal A Aizer Journal: JAMA Oncol Date: 2019-05-01 Impact factor: 31.777
Authors: Anita Mahajan; Salmaan Ahmed; Mary Frances McAleer; Jeffrey S Weinberg; Jing Li; Paul Brown; Stephen Settle; Sujit S Prabhu; Frederick F Lang; Nicholas Levine; Susan McGovern; Erik Sulman; Ian E McCutcheon; Syed Azeem; Daniel Cahill; Claudio Tatsui; Amy B Heimberger; Sherise Ferguson; Amol Ghia; Franco Demonte; Shaan Raza; Nandita Guha-Thakurta; James Yang; Raymond Sawaya; Kenneth R Hess; Ganesh Rao Journal: Lancet Oncol Date: 2017-07-04 Impact factor: 41.316
Authors: Samrat M Sanghvi; Jonathan W Lischalk; Ling Cai; Sean Collins; Mani Nair; Brain Collins; Keith Unger Journal: Radiat Oncol Date: 2017-02-28 Impact factor: 3.481
Authors: Nasser K Yaghi; Stephanie Radu; Joseph G Nugent; David J Mazur-Hart; Brandi W Pang; Stephen G Bowden; Blair Murphy; Seunggu J Han Journal: Neurooncol Pract Date: 2022-02-02
Authors: Cindy Franklin; Peter Mohr; Leonie Bluhm; Imke Grimmelmann; Ralf Gutzmer; Friedegund Meier; Marlene Garzarolli; Michael Weichenthal; Claudia Pfoehler; Rudolf Herbst; Patrick Terheyden; Jochen Utikal; Jens Ulrich; Dirk Debus; Sebastian Haferkamp; Martin Kaatz; Andrea Forschner; Ulrike Leiter; Dorothee Nashan; Alexander Kreuter; Michael Sachse; Julia Welzel; Lucie Heinzerling; Frank Meiss; Carsten Weishaupt; Thilo Gambichler; Gerhard Weyandt; Edgar Dippel; Kerstin Schatton; Eren Celik; Maike Trommer; Iris Helfrich; Alexander Roesch; Lisa Zimmer; Elisabeth Livingstone; Dirk Schadendorf; Susanne Horn; Selma Ugurel Journal: J Immunother Cancer Date: 2022-06 Impact factor: 12.469
Authors: Joseph A Carnevale; Brandon S Imber; Graham M Winston; Jacob L Goldberg; Ase Ballangrud; Cameron W Brennan; Kathryn Beal; Viviane Tabar; Nelson S Moss Journal: J Neurosurg Date: 2021-09-10 Impact factor: 5.408
Authors: Charlton Tsai; Bastien Nguyen; Anisha Luthra; Joanne F Chou; Lara Feder; Laura H Tang; Vivian E Strong; Daniela Molena; David R Jones; Daniel G Coit; David H Ilson; Geoffrey Y Ku; Darren Cowzer; John Cadley; Marinela Capanu; Nikolaus Schultz; Kathryn Beal; Nelson S Moss; Yelena Y Janjigian; Steven B Maron Journal: JAMA Netw Open Date: 2022-08-01
Authors: William C Newman; Jacob Goldberg; Sergio W Guadix; Samantha Brown; Anne S Reiner; Katherine Panageas; Kathryn Beal; Cameron W Brennan; Viviane Tabar; Robert J Young; Nelson S Moss Journal: J Neurooncol Date: 2021-06-19 Impact factor: 4.506